CTH-004 / Cartherics - LARVOL DELTA

Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China (BioSpace) - "Cartherics Pty Ltd...announced today that it has granted Shunxi Holding Group Co Ltd ('Shunxi') a licence to develop, manufacture and commercialise Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including ovarian cancer in Greater China. CTH-004 has shown promising results in animal models of ovarian cancer and will be evaluated in a clinical trial under a research and development collaboration with the Peter MacCallum Cancer Centre, announced earlier this year....This agreement provides Shunxi Holding Group a licence to develop, manufacture and commercialise CTH-004 for Greater China (Including Mainland China, Hong Kong, Macao and Taiwan), as well as an option to negotiate rights to other CAR-T products that incorporate the licenced IP."

Licensing / partnership • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

CRISPR/Cas9-induced knock-out of DGKαζ in TAG-72 CAR-T cells improves function and persistence in ovarian cancer (ESMO-TAT 2023) - "In contrast, administration of CTH-004 CAR-T cells completely ablated the tumours, with CAR-T cells still observable at the remnants of the tumour site 100 days following treatment. Conclusions The combination of TAG-72 CAR-T cells with deletion of DGKαζ provides improved tumour control, probably via either increased T cell killing and / or enhanced longevity."

CAR T-Cell Therapy • Oncology • Ovarian Cancer • Solid Tumor • TAG-72